Fennec Pharmaceuticals Inc. (FENC) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Research Triangle Park, NC, 미국. 현재 CEO는 Robert C. Andrade.
FENC 을(를) 보유 IPO 날짜 2017-09-15, 32 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $178.63M.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
